Apelin polypeptides

US10941182B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Jerry Ryan HOLDER · Simi Valley, US
• Gayathri Swaminath · Brisbane, US
• Michael J. Frohn · Thousand Oaks, US
• Brian Alan LANMAN · Calabasas, US
• Anthony B. Reed · Newbury Park, US
• Leslie P. Miranda · Thousand Oaks, US
• John Gordon Allen · Newbury Park, US
• Alexander J. Pickrell · Westlake Village, US
• Aaron C. Siegmund · Ventura, US
• Lewis D. Pennington · Ventura, US
• Bryant Yang · Simi Valley, US

Key dates

• Filing date: Jun 10, 2015
• Grant date: Mar 9, 2021
• Expiry date: May 26, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.